Introducing Human Metabolic and Hormone Assays

Bio-Rad Laboratories, Inc. announced the launch of its new Bio-Plex Pro RBM Human Metabolic and Hormone Assays. Developed in partnership with Myriad RBM, Inc., these multiplex immunoassays permit robust and simultaneous quantification of a highly relevant set of protein biomarkers for the study of diabetes, obesity, and metabolic syndrome, as well as related conditions such as cardiovascular disease and inflammation.

To better understand the relationship between metabolic and cardiovascular conditions, researchers need to study a wide range of disease-associated biomarkers, including gut and pituitary hormones, acute phase proteins, adipokines, nutrient-binding proteins, and growth factors. Because these biomarkers often act in concert, researchers would benefit greatly from the ability to simultaneously measure multiple analytes in a single blood or cell culture sample. The new Bio-Plex Pro RBM Human Metabolic and Hormone Assays were designed to meet this need.

Bio-Plex Pro RBM Human Metabolic and Hormone Assays comprise seven distinct multiplex panels for the detection of 39 analytes, of which 15 are unique to Bio-Rad’s panels. Myriad RBM’s collaboration with Sanofi and the Population Health Research Institute (PHRI) in testing samples from the ORIGIN diabetes clinical trial was instrumental in the selection of markers in these panels.

Benefits of Bio-Plex Pro RBM Assays include:

• Robust performance — validated to meet rigorous analytical standards and manufactured in accordance with GMP guidelines
• Reproducible data — lot-to-lot correlation specification of R² ≥ 0.9 based on sample testing
• Rapid results — multiplex data in just 3.5 hours through the use of magnetic beads and the fastest assay protocols

Bio-Plex Pro RBM Human Metabolic and Hormone Assays are compatible with the Bio-Plex^® 100/200, Bio-Plex 3D, and Bio-Plex^® MAGPIX™ Platforms, as well as all other Luminex-based xMAP Instruments and Software.

Please visit www.bio-rad.com/bioplexpr for more information about Bio-Rad’s Bio-Plex product portfolio.

Bio-Rad Introduces Bio-Plex Manager™ MP Software Upgrade for All MAGPIX Multiplex Readers

Bio-Rad Laboratories, Inc. announced the release of its Bio-Plex Manager MP Software Upgrade, which runs on all Luminex-based MAGPIX readers. Users of Bio-Rad’s Bio-Plex® MAGPIX™ instruments have already benefited from the ease of use and improved instrument performance that Bio-Plex Manager MP software brings to multiplex experiments, and now, with Bio-Plex Manager MP Software Upgrade, these benefits are available on all Luminex-based MAGPIX readers.

Over the past decade and a half, life science researchers have relied on Luminex bead-based immunoassays to gain more information from less sample in less time. Bio-Rad’s years of experience with xMAP technology have provided the company with in-depth knowledge and an understanding of the needs of multiplex users, including their desire for automation and a simplified user experience.

The Bio-Plex Manager MP Software Upgrade brings the benefits of Bio-Plex Manager MP software, including automated instrument management, to all Luminex-based MAGPIX readers.

The Bio-Plex Manager MP Software Upgrade brings the benefits of Bio-Plex Manager MP software, including automated instrument management, to all Luminex-based MAGPIX readers.

Bio-Plex Manager MP software offers an automated instrument management function, a unique feature that guides routine maintenance of the instrument based on its current status and performance. This automated feature ensures high quality data and optimal performance by:

• Automatically loading start-of-day maintenance routines based on instrument status
• Monitoring performance during data acquisition, alerting the user of performance issues, and resolving those issues
• Recommending simple stepwise troubleshooting

All of these benefits are now available for all Luminex-based MAGPIX readers through the Bio-Plex Manager MP Software Upgrade.

For more information on Bio-Rad’s Bio-Plex product portfolio, please visit www.bio-rad.com/bioplex.

Development of a new cancer biomarker assay

The Centers for Disease Control and Prevention estimates that one in every four deaths in the United States is due to cancer, (and presumably the statistics are the same for Canada), yet approximately one-third of all cancer cases could be prevented if detected early enough. Bio-Rad has recently developed the Bio-Plex Pro human cancer biomarker panel 2, which employs a magnetic bead-based workflow to quantify cancer biomarkers in diverse matrices including serum, plasma, cell culture supernatant and many other sample types.

Read “Development and Validation of Bio-Plex Pro Huaman Cancer Biomarker Panel 2” to learn more.

Human Cancer Biomarker Assays

Bio-Plex Pro human cancer biomarker assays from Bio-Rad Laboratories are a unique blend of magnetic bead–based assays designed to meet the needs of the most discerning preclinical and clinical researchers.

The multiplex format enables robust and reproducible measurement of 34 biomarkers involved in:

• Angiogenesis
• Metastasis
• Cell proliferation
• Cell adhesion/migration
• Apoptosis
• Inflammation

Want to learn more? Click here.

Watch the video below for a general primer on Bio-Plex technology.

Multiplexing magnetic style

Luminex and Bio-Rad Laboratories recently announced a distribution deal that brings MAGPIX into the Bio-Plex® Instrument Family. Now, Bio-Plex fans can choose from the complete range of Luminex instruments and consumables.

Share results and make important research decisions quickly by multiplexing your immunoassays:-

• Save time by measuring your assays simultaneously.
• Use less sample to get more information.
• Choose from a wide range of multiplex assays.
• Easy analysis with market leading Bio-Plex Manager™ software.

Checkout the Luminex video below to learn more about the system.